Page 2 - தலைமை நிர்வாகி அதிகாரி டேவிட் ரிக்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Message : Required fields (Reuters) - Eli Lilly & Co employees have accused a factory executive of altering documents required by government regulators in an effort to downplay serious quality control problems at the U.S. plant producing the drugmaker s COVID-19 treatment, according to an internal Lilly complaint and a source familiar with the matter. The unsigned report, filed April 8 in Lilly s confidential employee complaint system and reviewed by Reuters, is the latest sign of manufacturing problems at the drug giant. The complaint asserts that the executive, a top quality official at the company s factory in Branchburg, New Jersey, rewrote findings by Lilly technical experts at the plant, which has been under investigation by the U.S. Food and Drug Administration, to make the conclusions appear more favorable to the company.

United statesNew jerseySouthern methodist universitySan franciscoLydia wibleMichele gershbergNathan cortezLeanne hickmanKathryn beiserDavid ricksMarisa taylorJulie marquisDan levineSteven lynnUs department of healthHuman services